Enfamil Testing Results
December 27, 2011 by staff
Enfamil Testing Results, Pediatric nutrition specialist Mead Johnson Nutrition Co. (MJN) on Tuesday saw its shares jumping higher in premarket trading, following a report of no bacteria found in its Enfamil baby formula.
A release Sunday morning noted that after “a new round of rigorous testing,” the formula has been declared safe for consumption. Last week, MJN shares were trounced following a scare that its Enfamil PREMIUM Newborn powdered formula could have been tainted with the Cronobacter (Enterobacter sakazakii) bacteria.
Major retailers like Wal-Mart (WMT), Safeway (SWY), and Walgreen (WAG) all voluntarily pulled the formula from store shelves amid the scare.
Mead Johnson shares rose $3.34, or +5.1%, in premarket trading Tuesday.
Shares of Mead Johnson Nutrition (MJN) have a 1.59% dividend yield, based on Friday’s closing stock price of $65.29. The stock has technical support in the $61-$65 price area. If the stock can firm up, we see overhead resistance around the all-time highs of $76-$77 a share.
Mead Johnson Nutrition Co. (MJN) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.